Magnesium sulfate for neuroprotection before preterm birth: Uptake and adherence in clinical practice after National Guideline Implementation Authors: Hanne Trap Wolf, Sofie Elise Gellert, Lene Drasbek Huusom, Mads Langager Larsen Published: 2026 ABSTRACT AbstractIntroductionMagnesium sulfate (MgSO4) administered before very preterm birth reduces the risk of cerebral palsy in surviving infants and is recommended in international guidelines. In April 2020, a national guideline for MgSO4 for fetal neuroprotection was introduced in Denmark. We evaluated clinical uptake and adherence following guideline implementation.Material and MethodsThis retrospective medical chart review study included women who delivered at gestational age 24 + 0 to 31 + 6 weeks of gestation at nine different Danish hospitals between April 2020 and December 2023. These departments handled around 50% of all deliveries in Denmark in this period. Data were obtained from electronic medical records. The primary outcome was administration of MgSO4 for fetal neuroprotection among eligible women. Secondary outcomes included temporal trends in uptake, differences by gestational age and hospital size, and documented reasons for non‐administration. Descriptive statistics were used to summarize uptake rates and patient characteristics, and comparisons were performed using appropriate statistical tests.ResultsA total of 583 eligible women were included. Overall, 481 women (83%) received MgSO4 for fetal neuroprotection; of these, 340 women (71%) received MgSO4 within 24 h of birth. Uptake was highest among women delivering before 28 weeks of gestation, where MgSO4 was administered in nearly all eligible cases. Among women delivering between 28 + 0 and 31 + 6 weeks, approximately one in five did not receive treatment. Uptake did not increase over the study period, suggesting early adoption followed by stable implementation. Large‐volume hospitals demonstrated higher treatment rates compared with smaller hospitals. The most frequent reasons for non‐administration were lack of guideline awareness/oversight at later gestational ages and rapid delivery or maternal/fetal instability at earlier gestations.ConclusionsFollowing the implementation of the national guideline, uptake of MgSO4 for fetal neuroprotection in Denmark was high but incomplete. Persistent gaps in treatment, particularly among women delivering after 28 weeks of gestation, indicate a need for targeted implementation strategies to improve adherence and ensure equitable neuroprotective care.Keywords: feasibility, implementation, magnesium sulfate, neuroprotection, preterm birth, preterm labor Abbreviation Magnesium sulfate Key Message National implementation of magnesium sulfate for fetal neuroprotection achieved high but incomplete uptake in Denmark. Approximately 20% of eligible women remained untreated, revealing persistent implementation gaps related to gestational age and delivery circumstances. INTRODUCTION Magnesium sulfate (MgSO4) is an evidence‐based intervention shown to reduce the risk of cerebral palsy in preterm infants when administered to their mothers shortly before birth at 32 weeks of gestation or earlier. Based on robust data from randomized controlled trials and meta‐analyses, 1 , 2 the use of MgSO4 for fetal neuroprotection has been endorsed by several international guidelines, including those from the World Health Organization, 3 the American College of Obstetricians and Gynecologists 4 and NICE. 5 In April 2020, the Danish Society of Obstetrics and Gynaecology published a national clinical guideline recommending the administration of MgSO4 for fetal neuroprotection in pregnancies at risk of delivery from 24 + 0 to 31 + 6 weeks' gestation. The guideline advises an intravenous loading dose of 5 g over 20–30 min using an infusion pump, followed by a maintenance dose of 1 g per hour for up to 24 h or until birth occurs, whichever comes first. If delivery does not occur within 24 h, an additional MgSO4 bolus is not routinely recommended and may be administered at the clinician's discretion. 6 , 7 The Danish guideline does not recommend a rescue bolus as standard treatment, instead leaving the decision to the clinician due to limited evidence. At present, there is no clear consensus regarding the optimal dosing regimen of MgSO4 when used for neuroprotection in preterm birth. The most recent meta‐analysis on this topic included, among others, a Danish study that applied a regimen consisting of a 5 g loading dose followed by a maintenance dose of 1 g/h. 8 Given the lack of consensus in this area, the Danish guideline recommended adopting the same neuroprotective dosing regimen used in Denmark for eclampsia prophylaxis. 6 This approach was chosen to enhance patient safety and to facilitate clinical implementation by maintaining a familiar and standardized protocol for healthcare staff. Two months before the national publication, the clinical guideline was presented, discussed, and approved at a national meeting attended by representatives from all Danish obstetric departments, followed by encouragement and an expectation of immediate national implementation. Nevertheless, no further official measures were introduced to support the real‐world implementation. However, successful implementation of clinical guidelines requires more than formal publication. Organizational readiness, staff education, and time‐sensitive clinical decision‐making play critical roles in ensuring effective uptake. A recent Swedish multicenter study demonstrated that, despite the introduction of guidelines, the national uptake of MgSO4 fell short of the recommended target during the first year of implementation. 9 To date, no formal evaluation has been published assessing the real‐world implementation of guidelines from the Danish Society of Obstetrics and Gynaecology. We therefore conducted a retrospective study based on medical chart review across all obstetric departments in the eastern half of Denmark to determine whether the national recommendations regarding MgSO4 for fetal neuroprotection in pregnancies at imminent risk of delivery between gestational age 24 + 0 to 31 + 6 were integrated into routine clinical practice. Our primary objective was to determine the proportion of eligible women who received MgSO4 for fetal neuroprotection. Secondary objectives included evaluating the timing of administration initiation and documenting reasons for non‐administration. MATERIAL AND METHODS This study was designed as a retrospective medical chart review study, including all nine obstetric departments in the eastern half of Denmark (Bornholm Hospital, Herlev Hospital, Hillerød Hospital, Holbæk Hospital, Hvidovre Hospital, Nykøbing Falster Hospital, Rigshospitalet in Copenhagen, Roskilde Hospital, and Slagelse Hospital). These departments handle around 50% of all deliveries in Denmark. 10 Women with imminent preterm birth before 28 weeks of gestation are all transferred to Rigshospitalet, which is the only hospital in Eastern Denmark designated to manage extremely preterm deliveries. If maternal transfer is not feasible due to advanced labor or imminent delivery, a specialized neonatal acute transport team is dispatched to the local hospital to attend the birth. All hospitals in Eastern Denmark are situated less than a 1.5‐h drive from Rigshospitalet. Following initial stabilization, the newborn is transferred to the neonatal intensive care unit at Rigshospitalet. We defined Herlev Hospital, Hvidovre Hospital, and Rigshospitalet, each having more than 5000 deliveries annually, as major hospitals. Bornholm Hospital, Hillerød Hospital, Holbæk Hospital, Nykøbing Falster Hospital, Roskilde Hospital, and Slagelse Hospital, all having fewer than 5000 deliveries annually, were defined as minor hospitals. The study period spanned from July 1, 2020, to December 31, 2023, covering the first 3 years after the implementation of the guidelines. All women who gave birth at gestational age 24 + 0 to 31 + 6 at one of the participating hospitals during the study period without a diagnosis of preeclampsia (ICD10 O14), eclampsia (ICD10 O15), or hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome) (ICD10 O14.2) were eligible for inclusion in the study. Women who received MgSO4 but delivered after 32 weeks were not captured; however, this study focuses specifically on adherence to the national guideline for very preterm deliveries, and such cases were therefore outside the scope. Women were excluded if the child was stillborn or a case of late termination of pregnancy due to medical reasons. Women giving birth before 24 weeks of gestation were excluded from the primary analysis, as the Danish national guideline on neuroprotection leaves treatment before this gestational age optional at the clinician's discretion, with no clear recommendation for universal use. 6 We defined treatment according to the guideline as giving at least a full loading dose before delivery. Eligible cases were identified through the Epic electronic health record system, used across the participating hospitals in Eastern Denmark. Cases of preterm deliveries were identified through a combination of diagnosis codes and gestational age thresholds. Data were extracted by electronic medical record review by three medical doctors (HTW, SEG, and MLL), all specializing within obstetrics and gynecology, using a predefined and standardized registration form in REDCap. 11 We reviewed all medical records from the first admission to the obstetric department until delivery. The following data were extracted: Maternal age, hospital of delivery, date of delivery, gestational age at delivery, mode of delivery (vaginal or cesarean section), date, the timing of administration initiation, and documenting reasons for non‐administration, start of administration of MgSO4 (full loading dose, discontinued loading dose, start maintenance dose), time interval from start of treatment, if infusion was stopped due to maternal adverse effects, reasons for non‐administration, and reason for hospitalization. Reasons for hospitalization were divided into spontaneous preterm contractions, short cervix, preterm premature rupture of membranes, infection, bleeding, fetal growth restriction/flow changes, and other. The “other” category reflects rare but identified causes rather than unknown etiologies and included conditions, such as fetal pulmonary hemorrhage, preterm birth related to drainage procedures for twin‐to‐twin transfusion syndrome, and severe maternal illness (including, COVID‐19, aortic dissection, and cancer). The reason for hospitalization was categorized at the time of data extraction based on predefined categories, rather than extracted verbatim from the medical records. “Lack of guideline awareness” was defined based on documentation in the medical records. If there was no mention of any consideration regarding MgSO4 administration, this was categorized as a lack of guideline awareness. However, if it was stated that MgSO4 was not administered due to very rapid labor progression or likewise, this was not classified as a lack of guideline awareness. Women were categorized as treated (any MgSO4 treatment) or untreated (no MgSO4 treatment) and further subcategorized based on the timing of administration in relation to birth (< 1 h, 1–24 h, and > 24 h). The primary outcome was the proportion of eligible women who received MgSO4 in accordance with the national guideline. 6 Secondary outcomes included timing of administration relative to delivery and reasons for non‐administration. We did not include the total cumulative dose as this was not the focus of the present study. Descriptive statistics were used to summarize baseline characteristics and treatment patterns. Continuous variables were reported as means with standard deviations (SD) or medians with interquartile ranges (IQR), as appropriate. Categorical variables were presented as frequencies and percentages. Time from start of injection with MgSO4 to birth was noted in hours. Differences in continuous variables were compared using an independent‐samples t‐test and the Mann–Whitney test. Differences in proportions were tested using the chi‐squared test or Fisher's exact test, as appropriate. Trends in MgSO4 use over time were evaluated using the Cochran–Armitage test for trend. Data management and statistical analyses were performed using the R statistical software (version 2025.05.1 + 513) 12 and a two‐sided p‐value < 0.05 was considered statistically significant. RESULTS A total of 699 women gave birth before 32 weeks of gestation without a diagnosis of preeclampsia, eclampsia, or HELLP syndrome at the participating hospitals during the study period. Of these, 100/699 (14%) were excluded because of stillbirths or termination of pregnancy for medical reasons. No unexpected stillbirths were identified. A further 16/599 (3%) women gave birth before 24 + 0 weeks of gestation. Of these, 8/16 (50%) received MgSO4. These women were excluded from further analyses. The final study cohort comprised 583 women with a median gestational age of 29 + 4 weeks (IQR 27 + 2–31 + 0) (Figure 1). Study flowchart. Among all eligible women, 482/583 (83%) received MgSO4 for fetal neuroprotection in accordance with the national guideline. Table 1 presents maternal and obstetric characteristics according to treatment status within each clinical subgroup. Women receiving MgSO4 and those untreated were comparable in age and mode of delivery. Uptake was higher among women delivering before 28 weeks of gestation, with 159/177 (90%) receiving MgSO4, compared with 323/406 (80%) among those delivering between 28 + 0 and 31 + 6 weeks (p = 0.004). Non‐administration was most common at later gestations, particularly after 29 weeks (Figure 2). MgSO4 administration also varied by the underlying reason for hospitalization (p < 0.001). Uptake was high among women admitted with short cervix 72/77 (94%), preterm premature rupture of membranes 126/143 (88%), infection 20/20 (100%), and fetal growth restriction/flow changes 48/56 (82%). (Table 1). The three major hospitals accounted for 431/583 (74%) of all included deliveries. Treatment proportions differed between major and minor hospitals, with 371/431 women (86%) treated in the major hospitals compared with 111/152 women (73%) in the minor hospitals (p < 0.001). TABLE 1Cohort characteristics according to MgSO4 administration.CharacteristicsTotal n Treated (MgSO4 administered)Untreated (MgSO4 not administered) p * Overall, n (%)583482 (82.7)101 (17.3) Maternal characteristics Age, years (mean [SD])31.4 (5.0)32.1 (5.5)0.22Gestational age, weeks and days (median [IQR])29 + 3 (4)30 + 2 (3)0.00624 + 0–27 + 6 weeks of gestation n (%)177159 (89.8)18 (10.2)0.00428 + 0–31 + 6 weeks of gestation, n (%)406323 (79.6)83 (20.4) Mode of delivery 0.12Cesarean section, n (%)216186 (86.1)30 (13.9)Vaginal birth, n (%)367296 (80.7)71 (19.3) Reason for hospitalization < 0.001Spontaneous preterm contractions, n (%)193153 (79.3)40 (20.7)Short cervix, n (%)7772 (93.5)5 (6.5)Preterm prelabor rupture of membranes, n (%)143126 (88.1)17 (11.9)Infection, n (%)2020 (100)0Bleeding, n (%)7550 (66.7)25 (33.3)Fetal growth restriction/flow changes, n (%)5648 (85.7)8 (14.3)Other, n (%)1913 (68.4)6 (31.6) Delivery setting < 0.001Departments with < 5000 deliveries/year (minor hospitals), n (%)152111 (73.0)41 (27.0)Departments with ≥ 5000 deliveries/year (major hospitals), n (%)431371 (86.1)60 (13,9)*Independent‐samples t‐test and Mann–Whitney for the continuous variable (age and gestational age); chi‐squared or Fisher's exact test for categorical variables, as appropriate. Percentages are row percentages and represent the proportion of women within each subgroup who did or did not receive MgSO4. Cohort characteristics according to MgSO4 administration. Independent‐samples t‐test and Mann–Whitney for the continuous variable (age and gestational age); chi‐squared or Fisher's exact test for categorical variables, as appropriate. Percentages are row percentages and represent the proportion of women within each subgroup who did or did not receive MgSO4. Distribution of gestational ages among women treated and not treated with magnesium sulfate (treated = blue, not treated = orange). The overall proportion of eligible women treated according to the national guideline did not change significantly over time (Cochran–Armitage test for trend, p = 0.53) (Figure 3). Over the study period, the proportion of eligible women receiving MgSO4 ranged from approximately 80% to 95% in major hospitals, and from approximately 60% to 90% in minor hospitals, with greater inter‐period variability in the minor hospitals (Figure 3). Proportion of eligible women treated with magnesium sulfate over time, stratified by hospital type (major = blue, minor = orange, overall = black). Major hospitals were defined as hospitals having more than 5000 deliveries annually. Minor hospitals were defined as hospitals having fewer than 5000 deliveries annually. Each point covers a 6‐month interval between the dates on the x‐axis, with 95% confidence intervals. Uptake remained stable with no significant trend. Among women treated with MgSO4, 340/482 (71%) started MgSO4 within 24 h of birth. This proportion was similar in minor 79/111 (71%) and major hospitals 261/371 (70%); p = 0.87. Moreover, among women who received MgSO4, 60/482 (12.4%) received only the loading dose because labor was too advanced to allow time for maintenance therapy whereas 422/482 (88%) received both the loading and maintenance doses. Also, among all treated, MgSO4 administration began less than 1 h before birth in 71/482 (15%), 1–24 h before birth in 269/482 (56%), and more than 24 h before birth in 142/482 (29%) (Figure 4). The median interval from treatment initiation to birth among treated women was 7 h (IQR 2–35). Among women treated more than 24 h before delivery (n = 142), 70/142 (49%) received a rescue bolus closer to delivery (median interval of treatment initiation to birth: 63 h [IQR 43–119]). Rescue bolus use varied across hospitals, ranging from 0% at Roskilde Hospital and Holbæk Hospital to 64% at Rigshospitalet (Herlev Hospital: 20%, Hillerød Hospital: 30%, Hvidovre Hospital: 46%, and Slagelse Hospital: 33%). Distribution of time from start of magnesium sulfate injection to birth among women delivering within 24 h. The black line represents a kernel density estimate, that is, a smoothed estimate of the distribution of observations across the a‐axis. Among untreated women (n = 101), the leading reasons for non‐administration were lack of guideline awareness/oversight in 52/101 (51%) and rapid delivery or maternal/fetal instability in 47/101 (46%), whereas two of 101 women (2%) declined the treatment (Table 2). Interestingly, no treatments were discontinued due to maternal adverse effects. TABLE 2Reason for non‐administration of MgSO4 by gestational age subgroup.Reason/GATotal (n = 101)24 + 0–27 + 6 weeks (n = 18)28 + 0–31 + 6 weeks (n = 83) p * Lack of guideline awareness/oversight, n (%)52 (51.5)4 (22.2)48 (57.8)0.02Rapid delivery or maternal/fetal instability, n (%)47 (46.5)13 (72.2)34 (41.0)Declined treatment, n (%)2 (2.0)1 (5.6)1 (1.2)*Chi‐squared test. Reason for non‐administration of MgSO4 by gestational age subgroup. Chi‐squared test. DISCUSSION In this regional multicenter study, which included more than half of all births before 32 completed weeks of gestation in Denmark, we found that 83% of eligible women received MgSO4 for fetal neuroprotection following publication of the national guideline and that the uptake remained stable during the first 3 years. Treatment with MgSO4 was more frequent in major hospitals and among women delivering before 28 weeks of gestation. The leading reasons for not treating with MgSO4 were lack of guideline awareness/oversight and rapid delivery or maternal/fetal instability. Our reported uptake during the first 3 years of implementation is comparable to that reported in a recent Swedish study, in which 79% of the eligible women received MgSO4 before preterm delivery. 9 However, our uptake was slightly lower than in a French study, where treatment rates reached 87% within 5 years of implementation, 13 and a Canadian implementation study reporting that approximately 90% received at least one course of MgSO4, with 82% receiving both the loading and maintenance doses. 14 Notably, we observed no temporal increase in treatment uptake among women at the beginning of the study period (Figure 3), which suggests an early and rapid adoption, followed by a plateau in implementation. In contrast, another pattern was observed in Sweden, where the proportion treated increased from 72% to 87% during their study period. 9 Notably, the Danish national guideline does not provide a quantitative target for MgSO4 administration, in contrast to the Swedish guideline, which may affect clinical decision‐making and cross‐country comparisons. In Denmark, beyond the dissemination of the new national guideline at the annual national scientific meeting, no specific implementation measures were introduced, leaving the adoption largely to each individual obstetric department. In our cohort, treatment coverage was higher in the three major hospitals, each with more than 5000 deliveries per year, reflecting their higher concentrations of high‐risk pregnancies and experienced perinatal teams. Because women with imminent delivery before 28 weeks of gestation are generally transferred to Rigshospitalet, the regional tertiary center, the higher uptake observed at earlier gestational ages may reflect greater familiarity with MgSO4 administration and stronger local implementation at this hospital and the two other major centers. The observed decline in treatment rates with increasing gestational age should therefore be interpreted in light of the organization of perinatal care in Eastern Denmark. Conversely, the lower coverage in smaller centers likely reflects the lower frequency of preterm births and, thus, reduced familiarity with such cases, emphasizing the need for continuous education and awareness initiatives, especially in these settings. It should be noted that the greater variability observed among minor hospitals may partly reflect random fluctuation related to the smaller number of eligible women treated at these centers, as indicated by the wider confidence intervals, rather than true differences in implementation over time. Our findings indicate that there remains potential to improve uptake in Denmark, particularly among women delivering after 27 weeks of gestation, where more than half were not treated due to a lack of guideline awareness/oversight. Among women delivering before 28 weeks, missing treatment was almost universal due to rapid deliveries or maternal/fetal instabilities. This leaves limited room for further improvement among women delivering before 28 weeks' gestation, which may reflect a ceiling effect in the group. Comparable international data using similar definitions are limited, making it difficult to determine whether this represents a consistent upper boundary of implementation or is specific to the present setting. Notably, the proportion of women treated with corticosteroids across all Danish regions for threatening preterm birth and fetal lung maturation before 34 weeks of gestation is approximately 90% 15 leaving room for improvement regarding MgSO4 treatment. Thus, we propose that future implementation of new clinical guidelines in Denmark should aim for uptake rates exceeding 90%. However, this will likely require a more comprehensive and multifaceted implementation strategy. The Canadian study demonstrated that e‐learning modules, educational rounds, focus group discussions, and surveys of barriers and facilitators were effective in increasing MgSO4 use. 14 Likewise, an Australian study showed that implementing a quality improvement program mainly based on the Plan‐Do‐Study‐Act method 16 increased the proportion of women receiving MgSO4 from 63% to 86% over a three‐year period. 17 Sustained improvements likely require more than dissemination alone – targeted feedback, education, and periodic audits appear essential to maintain adherence over time. Combined with structured team checklists and integration of order sets, these measures could provide a framework for implementing future guidelines. Timely administration within the optimal 24‐h window was less frequent at the earliest gestations. This likely reflects the unpredictability of imminent delivery in extreme preterm labor rather than non‐compliance. Nearly half of those receiving MgSO4 more than 24 h before delivery were given a rescue bolus, but re‐treatment practices varied substantially across hospitals, underscoring the need for clearer operational guidance. MgSO4 has well‐known side effects, and a recent Cochrane meta‐analysis reported an increased risk of treatment discontinuation due to maternal adverse effects. 1 However, no treatment discontinuations due to adverse effects were documented in our cohort, which may suggest good tolerability, although minor or undocumented adverse effects cannot be excluded in this retrospective design. Key strengths of this study include the comprehensive inclusion of all obstetric departments in Eastern Denmark, covering approximately half of all deliveries nationwide, as well as standardized data collection and manual chart validation, ensuring high data quality. Nationwide assessment of MgSO4 uptake using registers or administrative data is currently not feasible because there is no specific treatment code for MgSO4, preventing reliable data linkage. However, we do not expect MgSO4 uptake to differ in the Western half of Denmark. With similar rates of corticosteroid treatment across Danish regions in women with threatening preterm birth, we assume that MgSO4 administration is likely comparable as well. Future efforts to implement standardized coding for MgSO4 administration would facilitate larger‐scale monitoring and benchmarking, enabling evaluation of guideline implementation across all hospitals. The main limitations are the retrospective design and the lack of denominator data on all preterm labors, which preclude the assessment of adherence among all potentially eligible women. In addition, our analysis was conducted per woman, in line with the national guideline, which recommends MgSO4 administration based on maternal risk of preterm delivery, regardless of whether the pregnancy is singleton or multiple. We did not collect data on pregnancy multiplicity, which we acknowledge as a limitation when interpreting the generalizability of our findings. Furthermore, excluding births before 24 + 0 weeks should also be considered when interpreting our findings, as this may slightly affect the overall treatment proportion and limit direct comparability with studies that include births at lower gestational ages. Furthermore, reasons for non‐administration were derived from clinical documentation and the category “lack of guideline awareness/oversight” inferred from the absence of a documented clinical justification, introducing potential subjectivity and risk of misclassification; however, data collection followed a standardized approach and, in uncertain cases, records were reviewed by multiple assessors, although the categorization may still not fully capture the complexity of clinical decision‐making or contextual factors influencing treatment omission, and findings should therefore be interpreted with caution. CONCLUSION Following the implementation of a national guideline in 2020, MgSO4 was administered almost immediately to most eligible women at risk of preterm birth before 32 weeks of gestation. Furthermore, uptake rates were stable during the first 3 years of implementation, but higher in the three major hospitals. Nonetheless, approximately one in five eligible women did not receive the treatment, most commonly due to a lack of guideline awareness/oversight or rapid delivery. Although our findings confirm the widespread integration of MgSO4 as a neuroprotective measure into Danish obstetric practice, we also identified actionable targets for further quality improvement through sustained education and structured feedback mechanisms. The next steps will focus on refining adherence and timing precision, as well as increasing uptake at minor hospitals through local quality improvement committees. AUTHOR CONTRIBUTIONS HTW and MLL conceived and designed the study. HTW, SEG, and MLL collected all data. HTW, SEG, LDH, and MLL analyzed the data and wrote the manuscript. All authors provided intellectual input and approved the manuscript. FUNDING INFORMATION No funding was obtained. CONFLICT OF INTEREST STATEMENT Hanne Trap Wolf, Sofie Elise Gellert, Lene Drasbek Huusom, and Mads Langager Larsen have no conflicts of interest to declare. ETHICS STATEMENT All collected data were anonymized, and the study was approved September 19, 2024, by the regional Data Protection Agency (p‐2024‐17198). According to Danish legislation, ethics committee approval is not required for retrospective registry‐based studies without biological samples or patient contact. Supporting information Table S1. Distribution of maternal and obstetric characteristics within the MgSO4‐treated and untreated groups (column percentages). DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES Associated Data Supplementary Materials Table S1. Distribution of maternal and obstetric characteristics within the MgSO4‐treated and untreated groups (column percentages). Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.